Yes, it is safe to start mirtazapine in this patient with mild renal impairment and normal liver function.
With an eGFR of 68 mL/min/1.73 m² (mild renal impairment) and normal liver enzymes, mirtazapine can be initiated, though you should start at a lower dose and monitor closely.
Dosing Recommendations Based on Renal Function
According to the FDA label, mirtazapine clearance is reduced approximately 30% in patients with moderate renal impairment (GFR 11-39 mL/min/1.73 m²) and 50% in severe renal impairment (GFR <10 mL/min/1.73 m²) 1. Your patient's eGFR of 68 falls into the mild renal impairment category, where the impact on drug clearance is minimal.
Specific Dosing Strategy:
- Start with 15 mg once daily at bedtime (the standard starting dose)
- In mild renal impairment (eGFR 60-89), no mandatory dose reduction is required 1
- The FDA label specifically states that "lowest starting doses are appropriate for patients with moderate or greater renal impairment" 1, which does not apply to your patient
- Monitor for adverse effects, particularly sedation and dizziness, during the first 1-2 weeks
Hepatic Considerations
Your patient's normal ALT and AST are reassuring. The FDA label notes that hepatic impairment causes approximately 30% decreased clearance 1, but this is not relevant here. Mirtazapine can cause transaminase elevations in approximately 2% of patients 1, so baseline normal values are appropriate, and you should recheck liver enzymes if clinical symptoms develop.
Key Monitoring Parameters
During the first month:
- Watch for excessive sedation (most common adverse effect, occurring in 19% vs 5% placebo) 2
- Monitor for orthostatic hypotension, particularly given the renal impairment 1
- Assess for drowsiness, which peaks in the first month (incidence density 58.1 per 1000 patient-months) 3
Common pitfalls to avoid:
- Don't assume sedation means the dose is too high—paradoxically, sedation is more common at subtherapeutic doses (<15 mg) and often improves when the dose is increased to therapeutic levels 4
- Elderly patients with renal impairment have 30-40% lower clearance 1, so if your patient is elderly, consider starting at 7.5 mg despite the mild renal impairment
Pharmacokinetic Rationale
Mirtazapine is 75% renally excreted (with 15% fecal elimination) 1, but the parent compound undergoes extensive hepatic metabolism first 5. With mild renal impairment, the modest reduction in clearance does not necessitate dose adjustment, though it does warrant closer monitoring than in patients with normal renal function.
The elimination half-life of 20-40 hours 5 means steady state will be reached in 4-6 days, allowing you to assess tolerability before any dose escalation.
Bottom Line
Initiate mirtazapine 15 mg at bedtime, monitor for sedation and orthostatic symptoms during the first 2 weeks, and titrate to 30 mg after 10-14 days if tolerated and clinically indicated. The mild renal impairment does not contraindicate use but does warrant slightly more vigilant monitoring than in patients with normal renal function 1.